answer text |
<p>To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well
as independent expert advisors on the Commission on Human Medicines and its Expert
Working Groups, have completed the assessment of the quality, safety and efficacy
data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data
supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19
caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person
vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of
the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose
two in participants with or without evidence of prior infection with SARS-CoV-2 was
94.6% - a 95% credible interval of 89.9% to 97.3%).</p><p>There is currently no data
available regarding transmission of COVID-19 to others in a person who has been vaccinated
using any of the COVID-19 vaccines. There is also currently no data available for
any COVID-19 vaccine on the period after vaccination for which a person can remain
asymptomatic.</p>
|
|